Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009362 | 0.87 | BTK (0.54) | BTKLCKSRC | |
| SCHEMBL16008810 | 0.83 | BTK (0.54) | BTKLCKSRC | |
| SCHEMBL16016637 | 0.79 | PDE10A (0.51) | BTKPDE10APIM1PIM3PIM2 | |
| SCHEMBL16008897 | 0.76 | BTK (0.73) | BTKLCKSRCPIM1PIM2 | |
| SCHEMBL16008896 | 0.76 | BTK (0.73) | BTKLCKSRCPIM1PIM2 | |
| SCHEMBL30377235 | 0.74 | PDE10A (0.56) | BTKPDE10APIM1PIM3PIM2 | |
| SCHEMBL17628041 | 0.74 | PDE10A (0.56) | BTKPDE10APIM1PIM3PIM2 | |
| SCHEMBL17628044 | 0.74 | PDE10A (0.56) | BTKPDE10APIM1PIM3PIM2 | |
| SCHEMBL16008423 | 0.72 | BTK (0.79) | BTKLCKSRC | |
| SCHEMBL16008405 | 0.72 | BTK (0.61) | BTKLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | BTK 1/4885PDE10A 1849/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.